Overview

Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth

Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
Magnesium is neuroprotective in neonatal animal models of acquired hypoxic-ischemic and/or inflammatory cerebral lesions. It is associated with a significant reduction of perinatal death and cerebral palsy in some observational studies. The objective of the study is to assess if prenatal magnesium sulfate given to women at risk of preterm birth before 33 week's gestation is neuroprotective.
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital, Rouen
Collaborator:
Ministry of Health, France
Treatments:
Magnesium Sulfate